-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 4, 2021, Beijing time, the annual event of the global oncology community-the American Society of Clinical Oncology (ASCO) annual meeting officially kicked off.
The RATIONALE 302 study is a randomized, open-ended, multi-center global phase 3 clinical trial (NCT03430843), which aims to evaluate the effectiveness and safety of Baizian® versus the chemotherapy selected by the investigator as the second-line treatment for patients with advanced or metastatic ESCC Sex
The data of the RATIONALE 302 study announced at the ASCO annual meeting showed that: the main endpoint of the study-the median overall survival (OS) of the intention-to-treat (ITT) population was 8.
At the ASCO annual meeting, BeiGene also announced another Bezeran® monotherapy in the treatment of previously treated, locally advanced unresectable or metastatic microsatellite highly unstable (MSI-H)/mismatch repair defects ( dMMR) Phase 2 clinical study results in patients with solid tumors
It is reported that BeiGene is also extensively exploring the therapeutic combination of immune combination therapy, and announced the clinical trial design and results of three of the drug combinations at this ASCO annual meeting, including Baizian® combined with the anti-TIGIT antibody ociperlimab under development.
